1,5-anhydroglucitol

structure

Also Known As:

1,5-anhydro-D-glucitol; 1,5-anhydro-D-sorbitol; 1,5-anhydrosorbitol; 1,5-sorbitan; 1-deoxy-D-glucopyranose; 1-deoxy-D-glucose; 1-deoxyglucose; D-glucitol, 1,5-anhydro-; D-glucose, 1-deoxy-; aceritol; polygalitol

Networked: 206 relevant articles (11 outcomes, 26 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Deoxy Sugars: 6
  - Deoxyglucose: 2901
    - 1,5-anhydroglucitol: 206

Experts

1.	Selvin, Elizabeth: 18 articles (11/2020 - 03/2011)
2.	Coresh, Josef: 9 articles (11/2019 - 03/2011)
3.	Bao, Yuqian: 7 articles (01/2021 - 02/2015)
4.	Ma, Xiaojing: 7 articles (01/2021 - 02/2015)
5.	Zhou, Jian: 7 articles (01/2021 - 02/2015)
6.	Köttgen, Anna: 5 articles (11/2020 - 01/2017)
7.	Pankow, James S: 5 articles (11/2020 - 01/2016)
8.	Ouchi, Motoshi: 5 articles (03/2020 - 02/2013)
9.	Suzuki, Tatsuya: 5 articles (03/2020 - 02/2013)
10.	Koga, Masafumi: 5 articles (10/2019 - 10/2010)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 01/01/2021 - "Saliva 1,5-anhydroglucitol is associated with early-phase insulin secretion in Chinese patients with type 2 diabetes." 01/01/2017 - "Repeated 3-minute stair climbing-descending exercise after a meal over 2 weeks increases serum 1,5-anhydroglucitol levels in people with type 2 diabetes." 05/01/2015 - "1,5-anhydroglucitol is associated with early-phase insulin secretion in chinese patients with newly diagnosed type 2 diabetes mellitus." 06/13/2014 - "Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes." 03/01/2014 - "We found a strong association of type 2 diabetes with 1,5-anhydroglucitol (1,5-AG) in saliva (P = 3.6 × 10(-13)). "
2.	Glucose Intolerance 07/01/2001 - "The objective of the study was to determine the efficacy of 1,5-anhydro-D-glucitol (1,5 AG) for the prediction of gestational diabetes and gestational impaired glucose tolerance (GIGT). " 07/01/2001 - "The predictive value of serum 1,5-anhydro-D-glucitol in pregnancies at increased risk of gestational diabetes mellitus and gestational impaired glucose tolerance." 09/01/2001 - "Post-load glucose measurements in oral glucose tolerance tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycaemic state, in subjects with impaired glucose tolerance." 08/01/1999 - "The objectives of this study were (1) to elucidate the efficacy of 1,5-anhydroglucitol (1,5-AG), glycosylated hemoglobin, and fructosamine (FRA) as screening tests for non-insulin-dependent diabetes mellitus (NIDDM) or for impaired glucose tolerance (IGT) and (2) to perform an economic evaluation for each indicator. "
3.	Insulin Resistance 01/01/2013 - "The proportion of patients with T2DM significantly gradually increased, HbA1c and the homeostasis model assessment of insulin resistance were significantly elevated, and 1,5-anhydroglucitol (1,5-AG) was remarkably decreased with the progression of fibrosis. " 07/01/2013 - "However, the levels of HbA1c, fasting insulin, serum 1,5-anhydro-d-glucitol, and Homeostasis Model of Assessment-Insulin Resistance showed no appreciable changes. " 08/01/2009 - "Fasting blood glucose (BG), Homeostasis Model of Assessment for Insulin Resistance (HOMA-IR), HbA1c, and 1,5-anhydroglucitol values were used as predictors for exceeding various 2-hour BG cut-offs. " 02/01/1998 - "The metabolic parameters were evaluated before treatment and at week 4 of treatment as follows: glycemic excursions by M-value and 1,5-anhydro-D-glucitol (1,5-AG), insulin secretion by area under the curve of daily serum insulin (AUCinsulin), and insulin sensitivity by the K index of the insulin tolerance test (KITT). " 01/01/2015 - "We performed multivariate regression analyses to estimate the association between the homeostasis model assessment of insulin resistance (HOMA-IR) values and markers of glycemic control, including glycated haemoglobin (HbA1c), 1,5-anhydroglucitol (1,5-AG), and fasting plasma glucose (FPG) levels, after adjustment for potential confounders. "
4.	Neutropenia 08/18/2023 - "SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia." 06/01/2023 - "The use of this SGLT2 inhibitor resulted in a marked decrease of 1,5-anhydroglucitol which has an important role in the development of neutropenia in this condition. " 01/01/2022 - "Recently, several reports have shown that off-label treatment with empagliflozin (EMPA), an inhibitor of the renal glucose transporter SGLT2, decreased blood 1,5-anhydroglucitol (1,5-AG), and neutrophil 1,5-AG6P, thus resulting in a new therapeutic option for neutropenia and neutrophil dysfunction in patients. " 01/01/2020 - "Recently, SGLT2 inhibitors such as empagliflozin that reduce the plasma levels of 1,5-anhydroglucitol have been described as a new treatment option for the neutropenia and neutrophil dysfunction in patients with GSD Ib. " 01/01/2022 - "Neutropenia and neutrophil dysfunction found in deficiencies in G6PC3 and in the glucose-6-phosphate transporter (G6PT/SLC37A4) are due to accumulation of 1,5-anhydroglucitol-6-phosphate (1,5-AG6P), an inhibitor of hexokinase made from 1,5-anhydroglucitol (1,5-AG), an abundant polyol present in blood. "
5.	Glycogen Storage Disease IB 01/01/2020 - "Recently, SGLT2 inhibitors such as empagliflozin that reduce the plasma levels of 1,5-anhydroglucitol have been described as a new treatment option for the neutropenia and neutrophil dysfunction in patients with GSD Ib. " 07/01/2022 - "Recently, kidney sodium-glucose co-transporter-2 (SGLT2) inhibitors such as empagliflozin known to reduce plasma levels of 1,5-anhydroglucitol (1,5-AG) and its toxic derivatives in neutrophils, have been described as a new treatment option in case reports of patients with GSD-Ib from Europe and Asia. "

Related Drugs and Biologics

1.	Sodium-Glucose Transporter 2 Inhibitors
2.	Glucose (Dextrose)
3.	Fructosamine
4.	Insulin (Novolin)
5.	Hemoglobins (Hemoglobin)
6.	empagliflozin
7.	Glycated Hemoglobin (Glycosylated Hemoglobin)
8.	Indicators and Reagents (Reagents)
9.	Blood Glucose (Blood Sugar)
10.	Triglycerides (Triacylglycerol)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Activities of Daily Living (ADL)